Article Menu
Need Help?
No Article Versions Notes Found
Cite
Ciftciler, R.; Goker, H.; Buyukasik, Y.; Sayınalp, N.; Haznedaroglu, I.C.; Aksu, S.; Ozcebe, O.; Demiroglu, H. Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients. Hematol. Rep. 2020, 12, 8267. https://doi.org/10.4081/hr.2020.8267
Ciftciler R, Goker H, Buyukasik Y, Sayınalp N, Haznedaroglu IC, Aksu S, Ozcebe O, Demiroglu H. Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients. Hematology Reports. 2020; 12(1):8267. https://doi.org/10.4081/hr.2020.8267
Chicago/Turabian StyleCiftciler, Rafiye, Hakan Goker, Yahya Buyukasik, Nilgun Sayınalp, Ibrahim C. Haznedaroglu, Salih Aksu, Osman Ozcebe, and Haluk Demiroglu. 2020. "Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients" Hematology Reports 12, no. 1: 8267. https://doi.org/10.4081/hr.2020.8267
APA StyleCiftciler, R., Goker, H., Buyukasik, Y., Sayınalp, N., Haznedaroglu, I. C., Aksu, S., Ozcebe, O., & Demiroglu, H. (2020). Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients. Hematology Reports, 12(1), 8267. https://doi.org/10.4081/hr.2020.8267
